Myocardial Infarction Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, and Key Companies

February 14 23:34 2023
Myocardial Infarction Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 60+ key pharma and biotech companies are working on 62+ pipeline drugs in the Myocardial Infarction therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Myocardial Infarction Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Myocardial Infarction Market. 

The Myocardial Infarction Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Myocardial Infarction Pipeline Analysis

Myocardial Infarction Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Myocardial Infarction and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Myocardial Infarction market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates


Route of Administration

Myocardial Infarction pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as –

  • Intra-articular

  • Intraocular

  • Intrathecal

  • Intravenous

  • Ophthalmic

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

  • Transdermal


Molecule Type

Products have been categorized under various Molecule types, such as

  • Oligonucleotide

  • Peptide

  • Small molecule


Learn How the Ongoing Clinical & Commercial Activities will Affect the Myocardial Infarction Therapeutic Segment @

Myocardial Infarction Therapeutics Landscape

There are approx. 60+ key companies are developing therapies for Myocardial Infarction. Currently, GENERIUM Pharmaceuticals is leading the therapeutics market with its Myocardial Infarction drug candidates in the most advanced stage of clinical development. 

The Leading Companies in the Myocardial Infarction Therapeutics Market Include:

Zensun (Shanghai) Sci & Tech, Valo Health, Inc., Translational Sciences, Tenaya Pharma, Tasly Pharmaceuticals, SmartPharma, Shanghai Life Science & Technology, Serpin Pharma, Serca Pharmaceutical, Rubicon Biotechnology, R-Pharm, Rion, ResoTher Pharma, RegeneRx, Regencor, Recardio, Inc., Qurgen Inc., Philip Morris International Inc., Olatec Therapeutics, NuvOx Pharma, NEXEL Co., Ltd., MimeTech Srl, Mesoblast, Inc., Matricelf, MandalMed, LTT Bio-Pharma, Kancera, Jemincare, Inoterm, Innolife, Dexa Medica, DeckTherapeutics, Cynata Therapeutics, Beijing Northland Biotech Co., Ltd., Bayer, AstraZeneca, Arthersys, Inc, aptaTargets, APT Therapeutics, Aposcience, Acticor Biotech, Abcentra, and many others.

Myocardial Infarction Drugs Covered in the Report Include:

  • Asundexian: Bayer

  • ATH3G10: Athera Biotechnologies

  • Empagliflozin: Boehringer Ingelheim

  • EndoGuard: EndoProtech Inc.

  • FDY 5301: Faraday Pharmaceuticals

  • GNR 060: GENERIUM Pharmaceuticals

  • NVX 308: NuvOx Pharma

  • PROTHERACYTES: CellProthera

  • Selatogrel: Idorsia Pharmaceuticals

  • UMSC01: Ever Supreme BioTechnology

  • Zalunfiban: CeleCor Therapeutics

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @


Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Myocardial Infarction Current Treatment Patterns

4. Myocardial Infarction – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Myocardial Infarction Late Stage Products (Phase-III)

7. Myocardial Infarction Mid-Stage Products (Phase-II)

8. Myocardial Infarction Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Myocardial Infarction Discontinued Products

13. Myocardial Infarction Product Profiles

14. Key Companies in the Myocardial Infarction Market

15. Key Products in the Myocardial Infarction Therapeutics Segment

16. Dormant and Discontinued Products

17. Myocardial Infarction Unmet Needs

18. Myocardial Infarction Future Perspectives

19. Myocardial Infarction Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @


Other Trending Healthcare Reports By DelveInsight

Myocardial Infarction Market Outlook

Myocardial Infarction Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2019 to 2032.

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States